Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a hormone shot boost IVF success for women with endometriosis?

NCT ID NCT04356664

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving a GnRH agonist before a frozen embryo transfer can help women with endometriosis or adenomyosis get pregnant. About 180 women aged 18 to 36 will be randomly assigned to receive either standard hormone support or standard support plus one or two doses of GnRH agonist. The main goal is to see if the extra treatment increases the rate of clinical pregnancy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2021

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 36 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18 to 36 years (women ≥18 years to \<36 years) with endometriosis and / or adenomyosis * Having benefited from In vitro fertilisation /intracytoplasmic micro-injection with freeze all and for whom the frozen embryon transfer of a blastocyst is planned * A normal uterine cavity * An MRI showing endometriosis and / or adenomyosis during the inclusion visit * Having signed a consent form * Being affiliated to a Health Insurance Plan. Exclusion Criteria: * Patient aged \<18 years and ≥ 36 years * BMI\> 35 * History of implantation failures (≥ 2) * Endometrial alterations: synechiae, polyps, myomas, hyperplasia, hematometra * known hydrosalpinx uni or bilateral * MRI showing no endometriosis or adenomyosis * Hypersensitivity to GnRH, GnRH analogues, or any of the excipients of Decapeptyl 3 mg * Known hypersensitivity to estradiol * Known hypersensitivity to progesterone * Known hypersensitivity to acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs * Known hypersensitivity to folic acid * Known hypersensitivity to cefixime or an antibiotic in the cephalosporin group * Known hypersensitivity to levofloxacin or any other quinolone * History of tendinopathies related to the administration of fluoroquinolones * Epilepsy * Hypersensitivity to contrast agents for MRI * Known or suspected breast cancer or history of breast cancer * Known or suspected genital tract cancer or history of genital cancer * known or suspected estrogen-dependent malignant neoplasms * Undiagnosed genital haemorrhage * Untreated endometrial hyperplasia * History of idiopathic venous thrombo-embolic accident or evolving venous thrombo-embolic event (deep vein thrombosis, pulmonary embolism) * Recent or evolving arterial thromboembolic stroke (eg angina, myocardial infarction) * Acute liver disease or history of liver disease, until hepatic tests are normalized * Severe renal insufficiency * Severe, uncontrolled heart failure * Evolutionary gastroduodenal ulcer * History of asthma caused by the administration of salicylates or substances of similar activity, especially nonsteroidal anti-inflammatory drugs * GnRH Agonist Decapeptyl administered within 6 months prior to transfer * To be deprived of liberty or under guardianship * Pregnancy and breast feeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenomyosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hopital Foch

    RECRUITING

    Suresnes, 92150, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.